首页> 美国卫生研究院文献>Biomolecules >Novel Applications of Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Therapeutics
【2h】

Novel Applications of Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Therapeutics

机译:间充质干细胞源性外泌体在心肌梗死治疗中的新应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally, representing approximately a third of all deaths every year. The greater part of these cases is represented by myocardial infarction (MI), or heart attack as it is better known, which occurs when declining blood flow to the heart causes injury to cardiac tissue. Mesenchymal stem cells (MSCs) are multipotent stem cells that represent a promising vector for cell therapies that aim to treat MI due to their potent regenerative effects. However, it remains unclear the extent to which MSC-based therapies are able to induce regeneration in the heart and even less clear the degree to which clinical outcomes could be improved. Exosomes, which are small extracellular vesicles (EVs) known to have implications in intracellular communication, derived from MSCs (MSC-Exos), have recently emerged as a novel cell-free vector that is capable of conferring cardio-protection and regeneration in target cardiac cells. In this review, we assess the current state of research of MSC-Exos in the context of MI. In particular, we place emphasis on the mechanisms of action by which MSC-Exos accomplish their therapeutic effects, along with commentary on the current difficulties faced with exosome research and the ongoing clinical applications of stem-cell derived exosomes in different medical contexts.
机译:心血管疾病(CVD)是全球死亡率和发病率的主要原因,每年约占所有死亡人数的三分之一。这些情况的大部分以心肌梗塞(MI)或众所周知的心脏病发作为代表,这种情况发生在流向心脏的血流减少导致心脏组织受伤时。间充质干细胞(MSCs)是多能干细胞,由于其有效的再生作用,代表了有希望用于治疗MI的细胞疗法的载体。然而,目前尚不清楚基于MSC的疗法能够在多大程度上诱导心脏再生,还不清​​楚如何改善临床结果。外来体是由MSC(MSC-Exos)衍生而来,是已知对细胞内通讯有影响的小细胞外囊泡(EVs),最近作为一种新型无细胞载体出现,能够在靶心内赋予心脏保护和再生作用细胞。在这篇综述中,我们评估了MI背景下MSC-Exos的研究现状。特别是,我们着重研究MSC-Exos发挥其治疗作用的作用机制,并评述外泌体研究目前面临的困难以及干细胞来源的外泌体在不同医学背景下的临床应用进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号